Issue of shares

September 12, 2022
RNS Number : 0215Z
Renalytix PLC
12 September 2022

Renalytix plc

("Renalytix" or the "Company")


Issue of shares


NEW YORK and SALT LAKE CITY, 12 September, 2022 - Renalytix Plc (NASDAQ: RNLX) (LSE: RENX) announces that under the Company's Employee Share Purchase Plan (the "ESPP"), 131,412 new ordinary shares of £0.0025 each in the capital of the Company (the "Ordinary Shares") have been issued to settle the purchase of 65,706 American Depositary Shares, each representing two Ordinary Shares, by employees who participated in the ESPP. This was carried out at a subscription price of $1.768 per American Depositary Share (£0.76 per Ordinary Share). Further details in relation to the ESPP were contained in the Company's announcement of 2 September 2020.


An application has been made to the London Stock Exchange for the new Ordinary Shares to be admitted to trading on AIM. It is expected that admission of the 131,412 new Ordinary Shares to trading on AIM will become effective on, or around, 15 September 2022 ("Admission").


Total voting rights

Following Admission, the Company will have 74,891,844 Ordinary Shares in issue with each share carrying the right to one vote. The Company has no Ordinary Shares held in treasury. The total number of voting rights in the Company following Admission will therefore be 74,891,844.



For further information, please contact:


Renalytix plc

James McCullough, CEO

Via Walbrook PR


Stifel (Nominated Adviser, Joint Broker)

Tel: 020 7710 7600

Alex PriceNicholas Moore



Investec Bank plc (Joint Broker)

Tel: 020 7597 4000

Gary Clarence / Daniel Adams


Walbrook PR Limited

Tel: 020 7933 8780 or

Paul McManus / Lianne Applegarth / Alice Woodings

Mob: 07980 541 893 / 07584 391 303 / 07407 804 654

CapComm Partners

Tel: 415-389-6400 or

Peter DeNardo



About Renalytix

Renalytix (LSE: RENX) (NASDAQ: RNLX) is the global founder and leader in the new field of bioprognosis™ for kidney health. The company has engineered a new solution that enables early-stage chronic kidney disease progression risk assessment. The Company's lead product, KidneyIntelX™, has been granted Breakthrough Designation by the U.S. Food and Drug Administration and is designed to help make significant improvements in kidney disease prognosis, transplant management, clinical care, patient stratification for drug clinical trials, and drug target discovery (visit For more information, visit


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact or visit

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.